NextPharma adds prefilled syringe capability in Belgium

Will be able to handle syringes containing cytotoxic and non-cytotoxic products

NextPharma is adding a prefilled syringe capability at its Sterile Product Development Centre (SPDC) in Braine-l’Alleud, Belgium to meet customer demand for formulation development and manufacturing of pre-filled syringes containing both cytotoxic and non-cytotoxic products.

The SPDC will be equipped with semi-automatic syringe fillers with automatic stoppering units under vacuum in both the cytotoxic and non-cytotoxic units. These fillers are being configured to fill product aseptically in quantities typically used in Phase I and Phase II clinical trials. The first syringe filler is planned to be in operation in the first quarter of 2011.

The SPDC supports customers' development projects from pre-formulation and formulation through to investigational medicinal product manufacturing with lyophilisation for Phase I to Phase II clinical trials with scale-up capability to Phase III and commercial scale in NextPharma’s commercial manufacturing facility on the same site.

NextPharma has recently been acquired by Sun European Partners with a view to leveraging NextPharma’s strong track record, reputation and state of the art facilities, to grow the business both organically and by acquisition.

Companies